132
- Ben-Levy R, Paterson HF, Marshall CJ, Yarden
Y (1994) A single autophosphorylation site
confers oncogenicity to the Neu/ErbB-2
receptor and enables coupling to the MAP
kinase pathway. EMBO J 13:3302–3311 - Gowryshankar A, Nagaraja V, Eslick GD (2014)
HER2 status in Barrett’s esophagus & esopha-
geal cancer: a meta analysis. J Gastrointest
Oncol 5:25–35 - Bang YJ, Van Cutsem E, Feyereislova A, Chung
HC, Shen L, Sawaki A, Lordick F, Ohtsu A,
Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J,
Lehle M, Rüschoff J, Kang YK (2010)
Trastuzumab in combination with chemother-
apy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-
esophageal junction cancer (ToGA): a phase 3,
openlabel, randomised controlled trial. Lancet
376:687–697 - Flejou JF, Paraf F, Muzeau F, Fékété F, Hénin
D, Jothy S, Potet F (1994) Expression of
c-erbB-2 oncogene product in Barrett’s adeno-
carcinoma: pathological and prognostic corre-
lations. J Clin Pathol 47:23–26 - Nakamura T, Nekarda H, Hoelscher AH,
Bollschweiler E, Harbeck N, Becker K, Siewert
JR, Harbeck N (1994) Prognostic value of
DNA ploidy and c-erbB-2 oncoprotein overex-
pression in adenocarcinoma of Barrett’s esoph-
agus. Cancer 73:1785–1794 - Brien TP, Odze RD, Sheehan CE, McKenna
BJ, Ross JS (2000) Her-2/neu gene amplifica-
tion by FISH predicts poor survival in Barrett’s
esophagus- associated adenocarcinoma. Human
Pathol 31:35–39 - Rossi E, Grisanti S, Villanacci V, Della Casa D,
Cengia P, Missale G, Minelli L, Buglione M,
Cestari R, Bassotti G (2009) HER-2 overex-
pression/amplification in Barrett’s esophagus
predicts early transition from dysplasia to ade-
nocarcinoma: a clinico-pathologic study. J Cell
Mol Med 13:3826–3833 - Rossi E, Villanacci V, Bassotti G, Casa DD,
Missale G, Minelli L, Cestari R (2006) Her-2/
neu in Barrett esophagus: a comparative study
between histology, immunohistochemistry, and
fluorescence in situ hybridization. Diagn Mol
Pathol 15:125–130 - Rauser S, Weis R, Braselmann H, Feith M,
Stein HJ, Langer R, Hutzler P, Hausmann M,
Lassmann S, Siewert JR, Höfler H, Werner M,
Walch A (2007) Significance of HER2 low-
level copy gain in Barrett’s cancer: implications
for fluorescence in situ hybridization testing in
tissues. Clin Cancer Res 13:5115–5123 - Albrecht B, Hausmann M, Zitzelsberger H,
Stein H, Siewert JR, Hopt U, Langer R, Höfler
H, Werner M, Walch A (2004) Array based
comparative genomic hybridization for the
detection of DNA sequence copy number
changes in Barrett’s adenocarcinoma. J Pathol
203:780–788- Villanacci V, Rossi E, Grisanti S, Bassotti G,
Ferrari VD, Missale G, Minelli L, Cengia P,
Marini G, Cestari R (2008) Targeted therapy
with trastuzumab in dysplasia and adenocarci-
noma arising in Barrett’s esophagus: a transla-
tional approach. Minerva Gastroenterol Dietol
54:347–353 - Hu Y, Bandla S, Godfrey TE, Tan D, Luketich
JD, Pennathur A, Qiu X, Hicks DG, Peters JH,
Zhou Z (2011) HER2 amplification, overex-
pression and score criteria in esophageal adeno-
carcinoma. Mod Pathol 24:899–907 - Tominaga N, Gotoda T, Hara M, Hale MD,
Tsuchiya T, Matsubayashi J, Kono S, Kusano
C, Itoi T, Fujimoto K, Moriyasu F, Grabsch HI
(2016) Five biopsy specimens from the proxi-
mal part of the tumor reliably determine HER2
protein expression status in gastric cancer.
Gastric Cancer 19:553–560 - Gullo I, Grillo F, Molinaro L, Fassan M, De
Silvestri A, Tinelli C, Rugge M, Fiocca R,
Mastracci L (2015) Minimum biopsy set for
HER2 evaluation in gastric and gastro-esopha-
geal junction cancer. Endosc Int Open
3:E165–E170 - Lordick F, Al-Batran SE, Dietel M, Gaiser T,
Hofheinz RD, Kirchner T, Kreipe HH,
Lorenzen S, Möhler M, Quaas A, Röcken C,
Rüschoff J, Tannapfel A, Thuss-Patience P,
Baretton G (2017) HER2 testing in gastric
cancer: results of a German expert meeting.
J Cancer Res Clin Oncol 143:835–841 - Kumarasinghe MP, Morey A, Bilous M, Farshid
G, Francis G, Lampe G, McCue G, Von
Neumann- Cosel V, Fox SB (2017) HER2 test-
ing in advanced gastric and gastro-esophageal
cancer: analysis of an Australia-wide testing
program. Pathology 49(6):575–581 - Khoury T, Sait S, Hwang H, Chandrasekhar R,
Wilding G, Tan D, Kulkarni S (2009) Delay to
formalin fixation effect on breast biomarkers.
Mod Pathol 22:1457–1467 - Voduc D, Kenney C, TO N (2008) Tissue
microarrays in clinical oncology. Semin Radiat
Oncol 18:89–97 - Yamashita-Kashima Y, Shu S, Yorozu K,
Hashizume K, Moriya Y, Fujimoto-Ouchi K,
Harada N (2014) Importance of formalin fix-
ing conditions for HER2 testing in gastric can-
cer: immunohistochemical staining and
fluorescence in situ hybridization. Gastric
Cancer 17:638–647
Duminda Subasinghe et al.